CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335info@schallfirm.comwww.schallfirm.com
SOURCE: The Schall Law Firm
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Investing in biotech stocks can be risky, particularly in the clinical stage, since their success often hinges on the results of trial data and regulatory developments. Additionally, it can take years for pre-revenue companies to bring a potential blockbuster drug from the pipeline stage to the point where it generates meaningful profits. So, while biotech companies carry the potential for significant returns for patient investors, there's also the potential for significant volatility and risk when investing in this corner of the market.
One way to find higher-conviction picks is by tracking insider buying activity, which refers to purchases of company stock made by executives, board members, and major shareholders. When these investors buy stock with their own money, it's typically viewed as a bullish signal by the market.
With this in mind, here's a look at two biotech stocks - Dyne Therapeutics and Relmada Therapeutics - that are breaking out technically, and were recently targeted for insider buying by their own CEOs.
#1. Dyne Therapeutics
Dyne Therapeutics is a clinical-stage biotech company known for its proprietary FORCE platform, which it's using to develop a portfolio of therapeutic candidates aimed at addressing the challenges of genetically driven muscle diseases.
The company's programs focus on conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy, each designed to target and potentially transform the treatment landscape for these serious disorders. The biotech company has a market cap of $3.0 billion.
Dyne's shares have been on a stellar run over the past year, soaring more than 273% in the past 52 weeks, and up 160% in 2024 alone. However, the stock has pulled back about 27% from its August highs.
CEO John Cox seems to like the stock around current levels, as the top executive purchased 32,000 shares of DYN on Sept. 4 at an average price of $33.04 per share, totaling an investment of just over $1 million. This marked the first insider buying activity on DYN since December 2022, and came almost immediately after the biotech stock dropped more than 30% in one session on Sept. 3.
DYN's nasty sell-off on Sept. 3 was sparked by a pair of updates that failed to impress investors. First, the company's Phase 1/2 DELIVER Trial of DYNE-251 in DMD patients yielded generally positive results, with “meaningful improvements in multiple functional endpoints”; however, there were also adverse safety events noted.
Perhaps most significantly for investors, the company announced the departure of several high-ranking executives simultaneously with the trial data, including its chief medical officer, chief operating officer, and chief business officer - which, for those who like to follow the moves of top company executives, provides noteworthy context for the next day's insider buying by the CEO.
As of the second quarter, DYN had a cash position of $778.8 million, which the company expects to fund operations into the second half of 2026.
DYN stock still has a unanimous "strong buy" rating from all 10 Wall Street analysts in coverage. The mean price target is $53, indicating expected upside potential of 53.2%.
#2. Relmada Therapeutics
Relmada Therapeutics is another clinical-stage biopharmaceutical company developing novel therapies for treating central nervous system (CNS) diseases. The company's lead product, REL-1017, is an NMDA receptor channel blocker currently in advanced clinical trials for the treatment of major depressive disorder. The company's market cap is a modest $91.4 million.
RLMD stock is down 15.8% on a YTD basis, but the shares have been gaining some serious momentum lately. The shares have spiked 85% from the 52-week lows set just last month, and RLMD is up more than 15% in today's session.
Today's rally is thanks to an upgrade to “buy” from “hold” at Jefferies, with the firm seeing a more favorable risk/reward ahead of expected Phase 3 trial results.
"REL-1017's two refined Phase III studies (RELIANCE-2/RELIGHT) in adjunct MDD may have a real chance of succeeding in YE:24/early 2025 and mid-2025, respectively," wrote analyst Andrew Tsai, who sees up to 10x potential for the shares, and raised his price target to $13 from $3.50.
Significantly, Jefferies isn't the only name feeling upbeat about RLMD. The biotech has been the subject of heavy insider buying this month, including by CEO Sergio Traversa, who purchased roughly $395,000 worth of shares at $2.82 each on Sept. 11. That marked the CEO's first purchase since January. Other notable insiders scooping up RLMD this September include CFO Maged Shenouda, Chair Charles Casamento, and Director Paul Kelly.
In Q2, the company reduced its research and development (R&D) expenses to $10.7 million, down by about 21% year over year as two Phase 3 trials concluded. Management projects that it has a sufficient cash position to fund operations through key milestones into 2025.
In addition to REL-1017, there's more in the pipeline. The REL-P11 trial is on pace to enter a Phase 1 study in Canada by the end of this year for its modified-release formulation of psilocybin, targeting metabolic diseases.
Analysts are slowly warming up to RLMD. Ahead of today's upgrade, the consensus stood at a "hold" rating for Relmada stock, consisting of 2 "strong buys," 2 "holds," and 1 "strong sell" rating.
The mean price target for RLMD is $10.12, representing a premium of about 189% to current levels.
On the date of publication, Nauman Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Dyne issued a press release on September 3, 2024, "announcing new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts." Despite this news, the Company announced in a second press release on the same day that its CMO, COO, and CBO were "stepping down from their roles." Based on this news, shares of Dyne cratered by 30.7%, harming investors.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335info@schallfirm.comwww.schallfirm.com
SOURCE: The Schall Law Firm
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.